S100P Expression Is a Novel Prognostic Factor in Hepatocellular Carcinoma and Predicts Survival in Patients with High Tumor Stage or Early Recurrent Tumors

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Yuan, Ray Hwang ^a   Chang, Ko Tung ^b   Chen, Yu Ling ^c   Hsu, Hey Chi ^a,c   Lee, Po Huang ^a   Lai, Po Lin ^a   Jeng, Yung Ming ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BETA CATENIN; CALCIUM BINDING PROTEIN; PROTEIN S100P; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BETA CATENIN GENE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEX DIFFERENCE; SURVIVAL TIME; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BETA CATENIN; CALCIUM-BINDING PROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84878981074     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065501     Document Type: Article

References (51)

1. Befeler AS, Di Bisceglie AM, (2002) Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122: 1609-1619.
2. Schafer DF, Sorrell MF, (1999) Hepatocellular carcinoma. Lancet 353: 1253-1257.
3. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, et al. (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98: 119-127.
4. Hsu HC, J TH, Lai PL, Lee PH, Peng SY, (1993) Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 53: 4691-4694.
5. Yuan RH, Jeng YM, Chen HL, Hsieh FJ, Yang CY, et al. (2005) Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, β-catenin mutation, and favorable prognosis. Clin Cancer Res 11: 2568-2575.
6. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, et al. (2006) Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209: 549-558.
7. Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, et al. (2007) Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res 13: 5368-5376.
8. Pan HW, Chou HY, Liu SH, Peng SY, Liu CL, et al. (2006) Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma. Cell Cycle 5: 2676-2687.
9. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, et al. (2007) Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 43: 736-744.
10. Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC, (2008) Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep 19: 1045-1053.
11. Yuan RH, Jeng YM, Hu RH, Lai PL, Lee PH, et al. (2011) Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg 15: 321-329.
12. Jiang H, Hu H, Tong X, Jiang Q, Zhu H, et al. (2012) Calcium-binding protein S100P and cancer: mechanisms and clinical relevance. J Cancer Res Clin Oncol 138: 1-9.
13. Guerreiro Da Silva ID, Hu YF, Russo IH, Ao X, Salicioni AM, et al. (2000) S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int J Oncol 16: 231-240.
14. Parkkila S, Pan PW, Ward A, Gibadulinova A, Oveckova I, et al. (2008) The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin Pathol 8: 2.
15. Sato N, Hitomi J, (2002) S100P expression in human esophageal epithelial cells: Human esophageal epithelial cells sequentially produce different S100 proteins in the process of differentiation. Anat Rec 267: 60-69.
16. Hsieh HL, Schäfer BW, Weigle B, Heizmann CW, (2004) S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem Biophys Res Commun 316: 949-959.
17. Heizmann CW, Ackermann GE, Galichet A (2007) Pathologies involving the S100 proteins and RAGE. Subcell Biochem 45.
18. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD, (2004) S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 279: 5059-5065.
19. Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, et al. (2007) RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 50: 1230-1240.
20. Koltzscher M, Neumann C, König S, Gerke V, (2003) Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P. Mol Biol Cell 14: 2372-2384.
21. Austermann J, Nazmi AR, Müller-Tidow C, Gerke V, (2008) Characterization of the Ca2+-regulated ezrin-S100P interaction and its role in tumor cell migration. J Biol Chem 283: 29331-29340.
22. Filipek A, Jastrzebska B, Nowotny M, Kuznicki J, (2002) CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family. J Biol Chem 277: 28848-28852.
23. Becker T, Gerke V, Kube E, Weber K, (1992) S100P, a novel Ca2+-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem 207: 541-547.
24. Schor AP, Carvalho FM, Kemp C, Silva ID, Russo J, (2006) S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast. Oncol Rep 15: 3-6.
25. Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE, et al. (2007) S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer 43: 1935-1943.
26. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, et al. (2003) Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 201: 63-74.
27. Ohuchida K, Mizumoto K, Egami T, Yamaguchi H, Fujii K, et al. (2006) S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res 12: 5411-5416.
28. Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, et al. (2008) Functional evidence implicating S100P in prostate cancer progression. Int J Cancer 123: 330-339.
29. Surowiak P, Maciejczyk A, Materna V, Drag-Zalesińska M, Wojnar A, et al. (2007) Unfavourable prognostic significance of S100P expression in ovarian cancers. Histopathology 51: 125-128.
30. Aishima S, Fujita N, Mano Y, Kubo Y, Tanaka Y, et al. (2011) Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am J Surg Pathol 35: 590-598.
31. Hamada S, Satoh K, Hirota M, Kanno A, Ishida K, et al. (2011) Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci 102: 150-156.
32. Tsai JH, Huang WC, Kuo KT, Yuan RH, Chen YL, et al. (2012) S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas. Histopathology 61: 1106-1116.
33. Kim JK, Jung KH, Noh JH, Eun JW, Bae HJ, et al. (2009) Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma. Int J Oncol 35: 1257-1264.
34. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, et al. (2000) β-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 157: 763-770.
35. Hsu HC, Peng SY, Lai PL, Chu JS, Lee PH, (1994) Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis. Int J Oncol 4: 1341-1347.
36. Edmonson HA, Steiner PE, (1954) Primary carcinoma of the liver: A study of 100 among 489,000 necropsies. Cancer (Phila) 7: 462-503.
37. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2010) AJCC cancer staging manual (7th ed). New York, NY: Springer.
38. Huang LR, Hsu HC, (1995) Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 55: 4717-4721.
39. Hsu HC, Cheng W, Lai PL, (1997) Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 57: 5179-5184.
40. Hsu HC, Huang AM, Lai PL, Chien WM, Peng SY, et al. (1994) Genetic alterations at the splice junction of p53 gene in human hepatocellular carcinoma. Hepatology 19: 122-128.
41. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, et al. (2004) High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and β-catenin mutations. Int J Cancer 112: 44-50.
42. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, Hansen M, Eloranta JJ, et al. (2005) Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol 166: 81-92.
43. Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, et al. (2010) Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 70: 2870-2879.
44. Arumugam T, Simeone DM, Van Golen K, Logsdon CD, (2005) S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 11: 5356-5364.
45. Du M, Wang G, Ismail TM, Gross S, Fernig DG, et al. (2012) S100P dissociates myosin IIA filaments and focal adhesion sites to reduce cell adhesion and enhance cell migration. J Biol Chem 287: 15330-15344.
46. Chandramouli A, Mercado-Pimentel ME, Hutchinson A, Gibadulinová A, Olson ER, et al. (2010) The induction of S100p expression by the Prostaglandin E2 (PGE2)/EP4 receptor signaling pathway in colon cancer cells. Cancer Biol Ther 10: 1056-1066.
47. Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, et al. (2012) Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res 14: R45.
48. Wang Q, Zhang YN, Lin GL, Qiu HZ, Wu B, et al. (2012) S100P, a potential novel prognostic marker in colorectal cancer. MOncol Rep 28: 303-310.
49. Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, et al. (2006) Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 66: 1199-1207.
50. Abd El, All H, (2007) Smooth muscle actin and s100p on non germinal centre diffuse large B cell lymphoma are adverse prognostic factors: pilot study. Diagn Pathol 2: 9.
51. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, et al. (2001) Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120: 1763-1773.